RecruitingNot ApplicableNCT05813457

Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis

Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis. Multicenter, Randomized Stepped-wedge Study


Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Enrollment

416 participants

Start Date

Jun 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The First-Episode Psychosis (FPE) is a severe disorder that can include delusions, cognitive disorders and suicidal behavior. In the majority of cases (more than 80%) it evolves into schizophrenia. Numerous studies show that the rapidity of the initial management of FPE would reduce the risk of negative evolution and would have a decisive impact on the short and long term prognosis. The rapidity of this management can be measured by the duration of untreated psychosis, or DUP (Duration of Untreated Psychosis), the time interval between the appearance of the first frank psychotic symptoms and the initiation of adequate psychiatric care. The objective of this study is to show the impact of an intervention facilitating access to specialized care for PEP on the reduction of DUP. This intervention consists of an early identification program for FPE, the PRESTO program, specifically targeting 3 determining steps in the reduction of DUP: * Informing the general population about psychotic disorders * Knowledge of front line actors (APL: general practitioners, school and university medicine, teenager's house, associative networks educators, emergency services, firefighters, etc.) about FPE and its management * Articulation between APL and specialized psychiatric care


Eligibility

Min Age: 15 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether an early identification program for first-episode psychosis can reduce the time between when symptoms start and when patients get treatment — a period called "duration of untreated psychosis" that strongly affects long-term outcomes. **You may be eligible if...** - You have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or a brief psychotic episode (per DSM-5 criteria) - You have never previously taken antipsychotic medication (except possibly for the current episode, and for less than 6 months) - You or your parents (if you are a minor) have given oral consent to participate **You may NOT be eligible if...** - You are already being followed and treated for a first-episode psychosis program - Your psychotic episode has already largely resolved (brief reactive psychosis) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPRESTO Early Identification Program

The program combines : 1. A population-based information component (information campaign aimed at the general population). 2. A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.). 3. Facilitated access to care for FPE patients in the form of a "pivot" mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)


Locations(6)

Hospices Civils de Lyon

Bron, France

Chu Clermont-Ferrand

Clermont-Ferrand, France

Chu Grenoble

Grenoble, France

CHU de Montpellier

Montpellier, France

CHU de Nîmes

Nîmes, France

Chu Saint Etienne

Saint-Etienne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05813457


Related Trials